Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Background: Hematoxylin and eosin (H&E) staining is widely considered to be the gold-standard diagnostic tool for histopathology evaluation. However, the fatty nature of some tissue types, such as breast tissue, presents challenges with cryo-sectioning, often resulting in artifacts that can make histopathologic interpretation and correlation with other imaging modalities virtually impossible. We present an optimized on-block H&E staining technique that improves contrast for identifying collagenous stroma during cryo-fluorescence tomography (CFT) sectioning.
View Article and Find Full Text PDFUveal metastasis: clinical characteristics, treatment, and prognostic factors in a cohort of 161 patients in China.
Can J Ophthalmol
January 2025
Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology &Visual Sciences Key Lab, Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Objective: To investigate the clinical and prognostic features of uveal metastasis in a Chinese population and compare these features across different primary cancers.
Design: Retrospective cross-sectional study.
Participants: 161 patients with uveal metastasis at Beijing Tongren Hospital.
High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts.
J Vis Exp
December 2024
Division of Exercise Physiology, Department of Health Professions, West Virginia University School of Medicine; Cancer Institute, West Virginia University School of Medicine; 3Department of Microbiology, Immunology, and Cell Biology, West Virginia University School of Medicine;
Article Synopsis
- Patient-derived xenografts (PDXs) offer a valuable approach to study breast cancer (BC) by mimicking real tumor environments and systemic effects, which in vitro models cannot achieve.
- A new method for orthotopic implantation of BC PDXs in immunodeficient mice eliminates the need for anesthesia, is less invasive, and allows for faster and scalable tumor model development.
- The validation process of the tumors includes assessing receptor status, confirming morphology, and verifying genetic similarity to patient samples, facilitating robust research across different BC subtypes.
Short-term Patient-Reported Outcomes Following Bilateral Risk-Reducing Mastectomy for Patients at a High Risk for Breast Cancer: A Systematic Review.
Ann Surg Oncol
January 2025
Department of Surgery, Duke University Medical Center, Durham, NC, USA.
Background: Bilateral risk-reducing mastectomies (RRMs) have been proven to decrease the risk of breast cancer in patients at high risk owing to family history or having pathogenic genetic mutations. However, few resources with consolidated data have detailed the patient experience following surgery. This systematic review features patient-reported outcomes for patients with no breast cancer history in the year after their bilateral RRM.
View Article and Find Full Text PDFUse of the Da Vinci SP surgical system in robot-assisted nipple-sparing mastectomy: a single-center, retrospective study.
Sci Rep
January 2025
Division of Breast Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-Gu, Seoul, 05505, Republic of Korea.
We investigated the safety and performance of the Da Vinci SP single-port robot (SP robot) in nipple-sparing mastectomy (NSM) with immediate reconstruction. Medical records of 60 women aged ≥ 19 years who had undergone SP robot-assisted unilateral or bilateral NSM with immediate reconstruction between October 2020 and August 2021 were retrospectively analyzed. Stage I (31, 47.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!